ADVISORY, Dec. 17, 2008 (GLOBE NEWSWIRE) --
What: Scott Santarella, Executive Director and COO of the Multiple Myeloma Research Foundation, will preside over the Opening Bell. Where: NASDAQ MarketSite - 4 Times Square - 43rd & Broadway - Broadcast Studio When: Thursday, December 18, 2008 at 9:15 - 9:30 a.m. ET Contact: Renee Leach (203) 652-0211 leachr@themmrf.org NASDAQ MarketSite: Jolene Libretto (646) 441-5220 Jolene.Libretto@NASDAQOMX.com
Feed Information:
The Opening Bell is available from 9:20 a.m. to 9:35 a.m. on Galaxy 28 C/9, downlink frequency 3880 horizontal. The feed can also be found on Ascent fiber 1623. If you have any questions, please contact Jolene Libretto at (646) 441-5220.
Radio Feed:
An audio transmission of the Opening Bell is also available from 9:20 a.m. to 9:35 a.m. on uplink IA6 C band / transponder 24, downlink frequency 4180 horizontal. The feed can be found on Ascent fiber 1623 as well.
Webcast:
A live webcast of the NASDAQ Opening Bell will be available at: http://www.nasdaq.com/reference/marketsite_about.stm.
Photos:
To obtain a hi-resolution photograph of the Market Open, please go to http://www.nasdaq.com/reference/marketsite_events.stm and click on the market open of your choice.
About Multiple Myeloma Research Foundation:
The Multiple Myeloma Research Foundation (MMRF) was established in 1998 as a 501(c)3 non-profit organization by twin sisters Karen Andrews and Kathy Giusti, soon after Kathy's diagnosis with multiple myeloma. The mission of the MMRF is to urgently and aggressively fund research that will lead to the development of new treatments for multiple myeloma. As the world's number-one private funder of multiple myeloma research, the MMRF has raised more than $100 million since its inception to fund more than 90 laboratories worldwide. The payback on its investment has been significant, including the approval of four new treatments in four years alone. Today, the MMRF is supporting 30 new compounds and approaches now in clinical trials and pre-clinical studies and has facilitated more than 15 clinical trials through its sister organization, the Multiple Myeloma Research Consortium (MMRC).
About NASDAQ OMX:
The NASDAQ OMX Group, Inc. is the world's largest exchange company. It delivers trading, exchange technology and public company services across six continents, with over 3,900 listed companies. NASDAQ OMX Group offers multiple capital raising solutions to companies around the globe, including its U.S. listings market; NASDAQ OMX Nordic, NASDAQ OMX Baltic, including First North; and the U.S. 144A sector. The company offers trading across multiple asset classes including equities, derivatives, debt, commodities, structured products and ETFs. NASDAQ OMX Group technology supports the operations of over 70 exchanges, clearing organizations and central securities depositories in more than 50 countries. NASDAQ OMX Nordic and NASDAQ OMX Baltic are not legal entities but describe the common offering from NASDAQ OMX Group exchanges in Helsinki, Copenhagen, Stockholm, Iceland, Tallinn, Riga, and Vilnius. For more information about NASDAQ OMX, visit http://www.nasdaqomx.com.